I. Introduction 1 II. Experimental Method & Materials 7 2.1 Animal procedures 7 2.2 Senescence-associated beta-galactosidase staining 7 2.3 RNA extraction and Real-Time PCR 8 2.4 ELISA 9 2.5 RNA-sequencing 10 2.6 Lipidomics 10 2.6.1 Reagents 10 2.6.2 Lipid extraction 10 2.6.3 TMSD methylation 11 2.6.4 Quantitative lipid analysis using LC-MS 11 2.6.5 Data processing and statistical analysis of the dataset obtained using MRM 12 2.7 Statistical analyses 12 III. Results 14 3.1 Vutiglabridin has no effect on body weight changes in aging mice 14 3.2 Vutiglabridin reduces the senescence phenotypes in the liver and eWAT 14 3.3 Vutiglabridin restores insulin sensitivity in eWAT 15 3.4 Vutiglabridin prevents FALC-induced inflammation in eWAT 18 3.5 Vutiglabridin improves NAD+ metabolism in eWAT 20 3.6 Vutiglabridin reduces inflammation in the aged liver by preventing TLO formation 20 3.7 Vutiglabridin enables mitochondria to function normally by allowing intact assembly of mitochondrial complex I 22 3.8 Vutiglabridin alleviates aging-related lipid profile changes 23 IV. Discussion 26 V. Conclusion 29 VI. Figures 30 VII. References 43
Research Interests
Protein Engineering; History and Philosophy of Science; Scientific Art; Biomaterial Development (Tissue Engineering) with modified bacteriophage; Bio Sensor Development